Among the different therapeutic agents evaluated for managing COVID-19, the most common that are registered for COVID-19 clinical trials are antivirals, monoclonal antibodies, and drugs modulating the renin–angiotensin system [17]. The gene discussed is REN; the disease is COVID-19.